Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income (2019 - 2025)

Historic Net Income for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.9 million.

  • Eton Pharmaceuticals' Net Income fell 40733.65% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 2191.21%. This contributed to the annual value of -$3.8 million for FY2024, which is 30844.02% down from last year.
  • Eton Pharmaceuticals' Net Income amounted to -$1.9 million in Q3 2025, which was down 40733.65% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Net Income ranged from a high of $5.1 million in Q1 2021 and a low of -$6.1 million during Q3 2021
  • For the 5-year period, Eton Pharmaceuticals' Net Income averaged around -$1.1 million, with its median value being -$1.6 million (2025).
  • In the last 5 years, Eton Pharmaceuticals' Net Income soared by 39261.87% in 2023 and then crashed by 40733.65% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Net Income (Quarter) stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then plummeted by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
  • Its Net Income was -$1.9 million in Q3 2025, compared to -$2.6 million in Q2 2025 and -$1.6 million in Q1 2025.